# Aimei Health Technology Co., Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Aimei Health Technology Co., Ltd.). ## Overview Aimei Health Technology Co., Ltd. is a blank check company formed to complete a merger, share exchange, asset acquisition, share purchase, recapitalization, or similar business combination. It has not yet generated operating revenue and has not identified a specific operating business beyond its announced proposed combination with United Hydrogen Group Inc. The company’s current activity is centered on holding IPO proceeds in trust, maintaining public-company compliance, and negotiating a transaction that would transform it into an operating business. Until a business combination closes, its value is driven by the quality of the target, the structure of the deal, and the amount of cash available in trust. ## Products & services {"• Special purpose acquisition company (SPAC) structure","• IPO proceeds held in trust for a future business combination","• Merger and acquisition transaction execution","• Public-company listing and shareholder approval process","• Sponsor-backed private placement units"} - **SPAC formation and capital raising** (0%) — IPO units, over-allotment proceeds, and sponsor private placement units used to fund the search for a target. - **Trust account management** (0%) — Cash and short-term U.S. government securities held in trust for public shareholders until a transaction closes or funds are returned. - **Business combination execution** (0%) — Negotiation, documentation, shareholder approval, and closing of a merger or similar acquisition transaction. - **Public company administration** (0%) — SEC reporting, legal, accounting, auditing, and due diligence activities required of a listed blank check company. - Special purpose acquisition company (SPAC) vehicle - Initial public offering of units and rights - Trust account holding of IPO proceeds - Business combination / merger transaction - Private placement units to sponsor affiliate - Public-company compliance and reporting ## Customers Aimei Health does not sell products or services to end customers in the normal operating sense; its current counterparties are investors, the sponsor, underwriters, and the target company in the proposed business combination. Public shareholders provide the IPO capital and hold redeemable interests tied to the eventual transaction outcome. Aimei Investment Ltd. is the sponsor-side investor that purchased private placement units and supports the SPAC structure. The proposed target, United Hydrogen Group Inc., is the operating business that would become the combined company if the merger closes. - **Public shareholders** (primary) — Investors who bought IPO units and rights and are effectively financing the search for and closing of a future business combination. - **Sponsor / private placement investor** (primary) — Aimei Investment Ltd. purchased private units to provide additional capital and align sponsor interests with the transaction process. - **Target company counterparty** (primary) — United Hydrogen Group Inc. is the operating business being acquired through the announced merger and is central to the company’s future value. - **Underwriters and service providers** (secondary) — Banks, legal counsel, auditors, and other advisors support the IPO, compliance, and transaction execution. - Public IPO investors buying units and rights for a future deal outcome - Sponsor affiliate Aimei Investment Ltd. buying private placement units - Underwriters and advisors providing capital markets and transaction services - Target company United Hydrogen Group Inc. as the merger counterparty - Shareholders voting on the proposed business combination ## Geography Aimei Health is incorporated as a Cayman Islands exempted company, while its trust account is located in the United States. The company’s current capital structure and public listing are U.S.-based, but the announced merger counterparty includes Cayman Islands entities, reflecting a cross-border SPAC transaction structure. Management states that it is not limited to any particular industry or geographic region when searching for a target. Because the company has no operating revenue yet, geography currently matters mainly through legal domicile, trust-account location, and the jurisdictional structure of the proposed merger. - Cayman Islands incorporation for the SPAC and merger structure - United States trust account holding IPO proceeds - U.S. public-market reporting and shareholder base - Cross-border transaction with Cayman Islands merger entities - No operating revenue geography yet because the company is pre-combination ## Strategy The company’s strategy is to complete an initial business combination and transition from a blank check vehicle into an operating business. Its disclosed path is the proposed merger with United Hydrogen Group Inc., which would provide the post-combination operating platform. Management must preserve shareholder support, satisfy closing conditions, and manage the timing risk embedded in the merger agreement. Until closing, the company’s strategic focus is on transaction execution, regulatory compliance, and maintaining sufficient liquidity to complete the deal process. - **Complete the proposed merger with United Hydrogen Group Inc.** (short-term) — The company has no operating business until a business combination closes, so transaction completion is the core value-creation event. - **Maintain liquidity and trust-account integrity** (short-term) — The company must preserve cash and manage public-company costs while the deal process is pending. - **Prepare for post-combination public-company operations** (medium-term) — If the merger closes, the combined company will need a functioning governance, reporting, and capital structure. - Close the announced business combination with United Hydrogen Group Inc. - Satisfy shareholder approval, regulatory, and closing conditions - Preserve trust-account value while the transaction remains pending - Manage sponsor alignment through private placement and lock-up terms - Transition from SPAC status to an operating public company ## Risks The company’s main risk is execution risk around the proposed business combination, because failure to satisfy closing conditions or obtain shareholder approval would leave it without an operating business. Timing risk is also material: the merger agreement includes a deadline and customary termination rights, so delays can jeopardize the transaction. As a SPAC, Aimei Health is exposed to redemption risk, financing risk, and the possibility that trust-account funds are insufficient to support the post-combination company or required redemptions. More broadly, blank check companies face regulatory, market, and valuation risk because investor sentiment, capital-market conditions, and target-company quality can change quickly before closing. - **Failure to complete the business combination** [critical] — The company has no operating business or revenue, so the announced merger is the primary path to becoming an operating company. - **Shareholder approval and closing-condition risk** [high] — The merger agreement can terminate if required approvals are not obtained or conditions are not satisfied by the deadline. - **Redemption and liquidity risk** [high] — Public shareholders may redeem, reducing cash available from the trust account for the combined company. - **Need for additional financing** [medium] — Management notes that additional financing may be required to complete the business combination or fund redemptions. - Merger may not close if conditions are not met or approvals fail - Transaction timing risk from deadline-based termination rights - Redemptions can reduce cash available for the combined company - Additional financing may be needed to complete or support the deal - Public-company compliance costs are high relative to current activity - No operating revenue means the company depends entirely on deal completion ## Accounting The key accounting issue is the treatment of IPO proceeds and the trust account, which are held for the benefit of public shareholders and generate interest income rather than operating revenue. Because the company has no operating business, reported results are driven by non-operating income from the trust account and by formation, legal, accounting, and due diligence costs. The deferred underwriting fee is contingent on closing a business combination, so it remains an important transaction-related liability until the deal is completed or fails. Investors should also watch for the accounting and presentation effects of any redemption activity, merger-related costs, and the transition from a blank check company to a consolidated operating business after closing. - **Trust account accounting** — Affects non-operating income, liquidity presentation, and shareholder redemption analysis - **Deferred underwriting fee** — Impacts transaction costs and cash available at closing - **Formation and operational costs** — Drives quarterly net income volatility - Trust-account interest income is the main source of reported income before closing - Formation and public-company costs create losses or reduce net income - Deferred underwriting fee is payable only if the business combination closes - Redemption-related accounting affects cash available for the transaction - Merger-related transaction costs can be significant relative to current activity - Post-close consolidation will change the accounting model entirely --- *Last updated: 2026-08-11T04:46:19.725192+00:00*